Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Nicola A Hanania, Suzanne C. Lareau & Barbara P. Yawn. (2017) Safety of inhaled long-acting anti-muscarinic agents in COPD. Postgraduate Medicine 129:5, pages 500-512.
Read now
Read now
Donald Banerji, Donald A. Mahler & Nicola A. Hanania. (2016) Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Review of Respiratory Medicine 10:7, pages 767-780.
Read now
Read now
Articles from other publishers (6)
James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran & Glenn Crater. (2019) Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine 153, pages 38-43.
Crossref
Crossref
S N Avdeev & N V Trushenko. (2019) New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease. Terapevticheskii arkhiv 91:3, pages 76-85.
Crossref
Crossref
David M. Halpin, Alan G. Kaplan & Richard K. Russell. (2017) Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respiratory Medicine 128, pages 28-41.
Crossref
Crossref
Paolo Giorgini, Paolo Di Giosia, Livia Ferri & Claudio Ferri. (2017) Cardiovascular events in patients with chronic obstructive bronchopulmonary disease. Journal of Cardiovascular Medicine 18, pages e23-e29.
Crossref
Crossref
Monika Laššánová, Štefan Laššán, Jana Tisoňová & Peter Krištúfek. (2016) Abstract. Klinická farmakologie a farmacie 30:1, pages 16-21.
Crossref
Crossref
Bryony Coupe, Andrew L. Griffiths & Gwyneth A. Davies. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
153
164
.